Biological treatment options for severe asthma in Poland

Intruduction and purpose: Patients with severe asthma account for approximately 3% to 10% of all asthma patients. They have higher hospital utilization rates and treatment costs than patients with non-severe asthma. Previously, treatment options for these patients were limited due to unacceptable si...

Full description

Saved in:
Bibliographic Details
Published in:Journal of education, health and sport health and sport, 2024-05, Vol.70, p.51135
Main Authors: Superson, Maciej, Wilk-Trytko, Klaudia, Szmyt, Katarzyna, Samojedny, Sylwia, Szymańska, Katarzyna, Walczak, Kamil, Krasnoborska, Julia, Zarębska, Julia
Format: Article
Language:English
Subjects:
asthma
asthma treatments
biologics
monoclonal antibodies
severe asthma
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page 51135
container_title Journal of education, health and sport
container_volume 70
creator Superson, Maciej
Wilk-Trytko, Klaudia
Szmyt, Katarzyna
Samojedny, Sylwia
Szymańska, Katarzyna
Walczak, Kamil
Krasnoborska, Julia
Zarębska, Julia
description Intruduction and purpose: Patients with severe asthma account for approximately 3% to 10% of all asthma patients. They have higher hospital utilization rates and treatment costs than patients with non-severe asthma. Previously, treatment options for these patients were limited due to unacceptable side effects. However, the advent of biologic therapies has provided promising targeted therapy for these patients. State of knowledge: Biologic therapies target inflammatory modulators that play a key role in the pathogenesis of asthma, particularly in patients with high T2 cells. These therapies have shown promising results in reducing asthma symptoms, improving lung function, decreasing the use of oral corticosteroids, and enhancing patients' quality of life. Conclusions: This article reviews the mechanism of action, efficacy, and indications of currently approved biologic drugs available in Poland, as well as potential therapeutic targets for the future.
doi_str_mv 10.12775/JEHS.2024.70.51135
format article
fullrecord <record><control><sourceid>doaj_cross</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_0101ef5fcee74b0396d722f13985a99e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_0101ef5fcee74b0396d722f13985a99e</doaj_id><sourcerecordid>oai_doaj_org_article_0101ef5fcee74b0396d722f13985a99e</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1555-356f796f347353ef67fa6587f433b2e7d9703854941c0d423b560b09e2782cca3</originalsourceid><addsrcrecordid>eNpNkM1KAzEUhYMoWGqfwE1eYMab3EkyWWqptlJQUNchk0nqlOmkJIPg29sfEVfncDh8i4-QWwYl40qJu-fF8q3kwKtSQSkYQ3FBJhw1K2oEefmvX5NZzlsAYPLwEzAh9UMX-7jpnO3pmLwdd34YadyPXRwyDTHR7L988tTm8XNnaTfQ19jbob0hV8H22c9-c0o-Hhfv82Wxfnlaze_XhWNCiAKFDErLgJVCgT5IFawUtQoVYsO9arUCrEWlK-agrTg2QkID2nNVc-csTsnqzG2j3Zp96nY2fZtoO3MaYtoYm8bO9d4AA-aDCM57VTWAWraK88BQ18Jq7Q8sPLNcijknH_54DMzJpTm6NEeXRoE5ucQfEPBlEw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Biological treatment options for severe asthma in Poland</title><source>DOAJ Directory of Open Access Journals</source><creator>Superson, Maciej ; Wilk-Trytko, Klaudia ; Szmyt, Katarzyna ; Samojedny, Sylwia ; Szymańska, Katarzyna ; Walczak, Kamil ; Krasnoborska, Julia ; Zarębska, Julia</creator><creatorcontrib>Superson, Maciej ; Wilk-Trytko, Klaudia ; Szmyt, Katarzyna ; Samojedny, Sylwia ; Szymańska, Katarzyna ; Walczak, Kamil ; Krasnoborska, Julia ; Zarębska, Julia</creatorcontrib><description>Intruduction and purpose: Patients with severe asthma account for approximately 3% to 10% of all asthma patients. They have higher hospital utilization rates and treatment costs than patients with non-severe asthma. Previously, treatment options for these patients were limited due to unacceptable side effects. However, the advent of biologic therapies has provided promising targeted therapy for these patients. State of knowledge: Biologic therapies target inflammatory modulators that play a key role in the pathogenesis of asthma, particularly in patients with high T2 cells. These therapies have shown promising results in reducing asthma symptoms, improving lung function, decreasing the use of oral corticosteroids, and enhancing patients' quality of life. Conclusions: This article reviews the mechanism of action, efficacy, and indications of currently approved biologic drugs available in Poland, as well as potential therapeutic targets for the future.</description><identifier>ISSN: 2391-8306</identifier><identifier>EISSN: 2391-8306</identifier><identifier>DOI: 10.12775/JEHS.2024.70.51135</identifier><language>eng</language><publisher>Kazimierz Wielki University</publisher><subject>asthma ; asthma treatments ; biologics ; monoclonal antibodies ; severe asthma</subject><ispartof>Journal of education, health and sport, 2024-05, Vol.70, p.51135</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-4541-0359 ; 0009-0005-3136-846X ; 0009-0005-6861-6359 ; 0000-0001-6891-9791 ; 0009-0009-1507-0347 ; 0000-0001-7883-0395 ; 0009-0006-4473-3347 ; 0009-0000-0302-4073</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,2096,27901,27902</link.rule.ids></links><search><creatorcontrib>Superson, Maciej</creatorcontrib><creatorcontrib>Wilk-Trytko, Klaudia</creatorcontrib><creatorcontrib>Szmyt, Katarzyna</creatorcontrib><creatorcontrib>Samojedny, Sylwia</creatorcontrib><creatorcontrib>Szymańska, Katarzyna</creatorcontrib><creatorcontrib>Walczak, Kamil</creatorcontrib><creatorcontrib>Krasnoborska, Julia</creatorcontrib><creatorcontrib>Zarębska, Julia</creatorcontrib><title>Biological treatment options for severe asthma in Poland</title><title>Journal of education, health and sport</title><description>Intruduction and purpose: Patients with severe asthma account for approximately 3% to 10% of all asthma patients. They have higher hospital utilization rates and treatment costs than patients with non-severe asthma. Previously, treatment options for these patients were limited due to unacceptable side effects. However, the advent of biologic therapies has provided promising targeted therapy for these patients. State of knowledge: Biologic therapies target inflammatory modulators that play a key role in the pathogenesis of asthma, particularly in patients with high T2 cells. These therapies have shown promising results in reducing asthma symptoms, improving lung function, decreasing the use of oral corticosteroids, and enhancing patients' quality of life. Conclusions: This article reviews the mechanism of action, efficacy, and indications of currently approved biologic drugs available in Poland, as well as potential therapeutic targets for the future.</description><subject>asthma</subject><subject>asthma treatments</subject><subject>biologics</subject><subject>monoclonal antibodies</subject><subject>severe asthma</subject><issn>2391-8306</issn><issn>2391-8306</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpNkM1KAzEUhYMoWGqfwE1eYMab3EkyWWqptlJQUNchk0nqlOmkJIPg29sfEVfncDh8i4-QWwYl40qJu-fF8q3kwKtSQSkYQ3FBJhw1K2oEefmvX5NZzlsAYPLwEzAh9UMX-7jpnO3pmLwdd34YadyPXRwyDTHR7L988tTm8XNnaTfQ19jbob0hV8H22c9-c0o-Hhfv82Wxfnlaze_XhWNCiAKFDErLgJVCgT5IFawUtQoVYsO9arUCrEWlK-agrTg2QkID2nNVc-csTsnqzG2j3Zp96nY2fZtoO3MaYtoYm8bO9d4AA-aDCM57VTWAWraK88BQ18Jq7Q8sPLNcijknH_54DMzJpTm6NEeXRoE5ucQfEPBlEw</recordid><startdate>20240517</startdate><enddate>20240517</enddate><creator>Superson, Maciej</creator><creator>Wilk-Trytko, Klaudia</creator><creator>Szmyt, Katarzyna</creator><creator>Samojedny, Sylwia</creator><creator>Szymańska, Katarzyna</creator><creator>Walczak, Kamil</creator><creator>Krasnoborska, Julia</creator><creator>Zarębska, Julia</creator><general>Kazimierz Wielki University</general><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-4541-0359</orcidid><orcidid>https://orcid.org/0009-0005-3136-846X</orcidid><orcidid>https://orcid.org/0009-0005-6861-6359</orcidid><orcidid>https://orcid.org/0000-0001-6891-9791</orcidid><orcidid>https://orcid.org/0009-0009-1507-0347</orcidid><orcidid>https://orcid.org/0000-0001-7883-0395</orcidid><orcidid>https://orcid.org/0009-0006-4473-3347</orcidid><orcidid>https://orcid.org/0009-0000-0302-4073</orcidid></search><sort><creationdate>20240517</creationdate><title>Biological treatment options for severe asthma in Poland</title><author>Superson, Maciej ; Wilk-Trytko, Klaudia ; Szmyt, Katarzyna ; Samojedny, Sylwia ; Szymańska, Katarzyna ; Walczak, Kamil ; Krasnoborska, Julia ; Zarębska, Julia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1555-356f796f347353ef67fa6587f433b2e7d9703854941c0d423b560b09e2782cca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>asthma</topic><topic>asthma treatments</topic><topic>biologics</topic><topic>monoclonal antibodies</topic><topic>severe asthma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Superson, Maciej</creatorcontrib><creatorcontrib>Wilk-Trytko, Klaudia</creatorcontrib><creatorcontrib>Szmyt, Katarzyna</creatorcontrib><creatorcontrib>Samojedny, Sylwia</creatorcontrib><creatorcontrib>Szymańska, Katarzyna</creatorcontrib><creatorcontrib>Walczak, Kamil</creatorcontrib><creatorcontrib>Krasnoborska, Julia</creatorcontrib><creatorcontrib>Zarębska, Julia</creatorcontrib><collection>CrossRef</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of education, health and sport</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Superson, Maciej</au><au>Wilk-Trytko, Klaudia</au><au>Szmyt, Katarzyna</au><au>Samojedny, Sylwia</au><au>Szymańska, Katarzyna</au><au>Walczak, Kamil</au><au>Krasnoborska, Julia</au><au>Zarębska, Julia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biological treatment options for severe asthma in Poland</atitle><jtitle>Journal of education, health and sport</jtitle><date>2024-05-17</date><risdate>2024</risdate><volume>70</volume><spage>51135</spage><pages>51135-</pages><issn>2391-8306</issn><eissn>2391-8306</eissn><abstract>Intruduction and purpose: Patients with severe asthma account for approximately 3% to 10% of all asthma patients. They have higher hospital utilization rates and treatment costs than patients with non-severe asthma. Previously, treatment options for these patients were limited due to unacceptable side effects. However, the advent of biologic therapies has provided promising targeted therapy for these patients. State of knowledge: Biologic therapies target inflammatory modulators that play a key role in the pathogenesis of asthma, particularly in patients with high T2 cells. These therapies have shown promising results in reducing asthma symptoms, improving lung function, decreasing the use of oral corticosteroids, and enhancing patients' quality of life. Conclusions: This article reviews the mechanism of action, efficacy, and indications of currently approved biologic drugs available in Poland, as well as potential therapeutic targets for the future.</abstract><pub>Kazimierz Wielki University</pub><doi>10.12775/JEHS.2024.70.51135</doi><orcidid>https://orcid.org/0000-0002-4541-0359</orcidid><orcidid>https://orcid.org/0009-0005-3136-846X</orcidid><orcidid>https://orcid.org/0009-0005-6861-6359</orcidid><orcidid>https://orcid.org/0000-0001-6891-9791</orcidid><orcidid>https://orcid.org/0009-0009-1507-0347</orcidid><orcidid>https://orcid.org/0000-0001-7883-0395</orcidid><orcidid>https://orcid.org/0009-0006-4473-3347</orcidid><orcidid>https://orcid.org/0009-0000-0302-4073</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2391-8306
ispartof Journal of education, health and sport, 2024-05, Vol.70, p.51135
issn 2391-8306
2391-8306
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_0101ef5fcee74b0396d722f13985a99e
source DOAJ Directory of Open Access Journals
subjects asthma
asthma treatments
biologics
monoclonal antibodies
severe asthma
title Biological treatment options for severe asthma in Poland
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T07%3A06%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biological%20treatment%20options%20for%20severe%20asthma%20in%20Poland&rft.jtitle=Journal%20of%20education,%20health%20and%20sport&rft.au=Superson,%20Maciej&rft.date=2024-05-17&rft.volume=70&rft.spage=51135&rft.pages=51135-&rft.issn=2391-8306&rft.eissn=2391-8306&rft_id=info:doi/10.12775/JEHS.2024.70.51135&rft_dat=%3Cdoaj_cross%3Eoai_doaj_org_article_0101ef5fcee74b0396d722f13985a99e%3C/doaj_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1555-356f796f347353ef67fa6587f433b2e7d9703854941c0d423b560b09e2782cca3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true